BIOMAT Database Logo BIOMAT Database Logo

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). 2006

N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France.

In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFalpha/beta genes impairs normal hematopoietic differentiation and is supposed to cooperate with additional mutations promoting proliferation. The incidence and the prognosis of receptor tyrosine kinase (RTK) c-Kit and FLT3 mutations and Ras mutations were evaluated in 103 pediatric and adult patients with CBF-AML. c-Kit mutations were present in 17% patients. c-Kit exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 versus 6%). Only one patient had FLT3-ITD but FLT3-D835 was as frequent as reported in AML population (7%). Ras mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 versus 8%, P=0.001). RTK mutations were associated with a higher white blood cell count (WBC) (36 versus 21 G/L, P=0.05). FLT3 mutations were significantly associated with a shorter EFS and survival (P<0.0001 and P=0.0002) owing to an excess of early events. c-Kit mutations were associated with a shorter EFS and RFS (P=0.002 and P=0.003) in t(8;21) but not inv(16) patients. As previously observed, Ras mutations did not affect prognosis. Screening for RTK mutations may help to identify patients with a more adverse outcome and thus susceptible to benefit from intensified protocols or RTK inhibitors.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005260 Female Females

Related Publications

N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.
June 2003, British journal of haematology,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
October 2011, Leukemia research,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).
August 2020, Molecular and clinical oncology,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
June 2022, Clinical lymphoma, myeloma & leukemia,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
March 2017, Hematology/oncology and stem cell therapy,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.
May 2014, Leukemia,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
May 1999, Blood,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Core binding factor acute myeloid leukaemia and c-KIT mutations.
May 2013, Oncology reports,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
September 2005, Leukemia,
N Boissel, and H Leroy, and B Brethon, and N Philippe, and S de Botton, and A Auvrignon, and E Raffoux, and T Leblanc, and X Thomas, and O Hermine, and B Quesnel, and A Baruchel, and G Leverger, and H Dombret, and C Preudhomme, and , and
Detection of KIT mutations in core binding factor acute myeloid leukemia.
January 2018, Leukemia research reports,
Copied contents to your clipboard!